Regulatory Insights

  1. Under Half Of CTIS Trials Met Results Reporting Requirements 8/14/2026

    A first assessment of compliance on EU Clinical Trial Information System (CTIS) found fewer than half of European Phase II–IV drug trials legally required to post results fully complied on time.

  2. The Regulatory Compass Driving Drug Delivery Innovation 8/12/2026

    Regulatory requirements are growing more complex. Discover how strategic planning, regulatory intelligence, and platform approaches can streamline development and approvals.

  3. MIDBA: A New Regulatory Approach To Clinical Device Bridging 8/12/2026

    When devices evolve, evidence expectations can shift. Explore a risk-based clinical bridging approach to support regulatory decisions.

  4. Matching Pharmacovigilance Methodology To Organizational Scale 8/12/2026

    One-size-fits-all doesn't work for safety signal detection. Discover a scalable framework that keeps expert judgment at the center — no matter how large your portfolio grows.

  5. Clinical Supply Flexibility Where Biotech Programs Need It Most 8/10/2026

    Flexible clinical development requires scalable infrastructure, strong project management, and global logistics to ensure supply continuity and regulatory compliance.

  6. Packaging And Labeling Support For A Global Cell Therapy Program 8/10/2026

    Master complex cell therapy logistics with coordinated depots, purpose-built labeling, and temperature-controlled solutions that protect product integrity.

  7. Improving Clinical Trial Label Translation Through Centralized Reuse And Control 8/10/2026

    Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.

  8. 7 Practical Implications Of ICH E6(R3) For Early-Phase Trial Design 8/10/2026

    A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.

  9. Speed Kills: When Timelines Trump Science In Neuropsychiatric Trials 8/4/2026

    This Bold Conversation brings together experts helping to define the next chapter of psychedelic clinical research to unpack lessons from recent regulatory reviews and explore what clinical teams need now.

  10. Accelerating Psychedelic Therapeutics: A Regulatory Inflection Point In Mental Health 8/4/2026

    A 2026 executive order is fast-tracking psychedelic therapies for depression, PTSD, and addiction. Understand what this regulatory shift means for your next clinical trial.